Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

Data from an interim analysis of the phase 3 randomized, double-blind DEB study—presented during the 2024 ASCO Annual Meeting—showed that patients with previously untreated DLBCL and double expression of MYC and BCL2 treated with tucidinostat (a sub-type selective HDAC inhibitor) plus R-CHOP experienced a 24-month event-free survival rate of 58.9% vs 46.2% among patients receiving placebo plus R-CHOP (HR 0.68 [95% CI, 0.49-0.94]; P = 0.018). Although the incidence of grade 3 or greater hematologic adverse events was higher in the tucidinostat group, most patients were able to tolerate and complete treatment.